Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Pulse Biosciences ( (PLSE) ) is now available.
On March 9, 2026, Pulse Biosciences reported long-term clinical durability data from its first-in-human feasibility study of the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodule ablation, based on follow-up of 21 patients monitored 15 to 22 months after treatment. Presented on March 6, 2026, at the North American Society for Interventional Thyroidology meeting, the data showed an average 74% reduction in nodule volume, continued volume decline over time, no nodule regrowth, no serious adverse events, and exceptionally high cosmetic and overall patient satisfaction.
The company highlighted that no intranodular fibrosis was detected on ultrasound at 15 to 22 months, underscoring the potential long-term safety profile of its nonthermal nsPFA energy. Executives and investigators framed the results as an early but important milestone in building clinical evidence for nsPFA in benign thyroid nodule treatment, strengthening Pulse Biosciences’ positioning as it evaluates broader non-cardiac applications and future market development for its nPulse platform.
The most recent analyst rating on (PLSE) stock is a Sell with a $18.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
The score is primarily constrained by very weak financial performance (minimal revenue, large losses, and rising cash burn), partially offset by a relatively supportive balance sheet. Clinical and regulatory progress from the latest earnings call improves the outlook, while technical signals are mixed and valuation support is limited due to negative earnings and no dividend.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences, Inc. is a bioelectric medicine company developing its proprietary nPulse technology, which delivers nanosecond pulsed field ablation (nsPFA) energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is pursuing applications in atrial fibrillation treatment and other soft tissue ablation markets where its nonthermal approach could materially improve outcomes for patients and providers.
Average Trading Volume: 321,504
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.23B
Learn more about PLSE stock on TipRanks’ Stock Analysis page.